A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures

Abstract Efforts to understand the tumor microenvironment through basic science research and the cancer genome atlas (TCGA) data analysis have led to the creation of unique immune transcriptomic signatures from tumor-infiltrating lymphocytes (TIL). However, no pan-cancer analysis has been conducted...

Full description

Saved in:
Bibliographic Details
Main Authors: Kyle J. Hitscherich, Darryl Nousome, Aaron J. Dinerman, Victoria Dulemba, Frank J. Lowery, Naris Nilubol
Format: Article
Language:English
Published: Springer 2025-08-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Online Access:https://doi.org/10.1007/s00262-025-04102-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849234686120820736
author Kyle J. Hitscherich
Darryl Nousome
Aaron J. Dinerman
Victoria Dulemba
Frank J. Lowery
Naris Nilubol
author_facet Kyle J. Hitscherich
Darryl Nousome
Aaron J. Dinerman
Victoria Dulemba
Frank J. Lowery
Naris Nilubol
author_sort Kyle J. Hitscherich
collection DOAJ
description Abstract Efforts to understand the tumor microenvironment through basic science research and the cancer genome atlas (TCGA) data analysis have led to the creation of unique immune transcriptomic signatures from tumor-infiltrating lymphocytes (TIL). However, no pan-cancer analysis has been conducted to compare the prognostic performance of these signatures using overall survival (OS) or progression-free interval (PFI) as endpoints. We compiled a library of 146 TIL-immune signatures and evaluated gene signature score correlation with OS and PFI for 9,961 available TCGA samples across 33 tumor types. Zhang CD8 TCS demonstrated higher accuracy in prognosticating both OS and PFI across the pan-cancer landscape; however, variability was seen across cancer types and germ cell origin. Cluster analysis compiled a group of six signatures (Oh.Cd8.MAIT, Grog.8KLRB1, Oh.TIL_CD4.GZMK, Grog.CD4.TCF7, Oh.CD8.RPL, Grog.CD4.RPL32) whose association with OS and PFI could potentially be conserved across multiple neoplasms.
format Article
id doaj-art-60ae6ca94ae34e5a9b4ec9e0d87a8169
institution Kabale University
issn 1432-0851
language English
publishDate 2025-08-01
publisher Springer
record_format Article
series Cancer Immunology, Immunotherapy
spelling doaj-art-60ae6ca94ae34e5a9b4ec9e0d87a81692025-08-20T04:03:03ZengSpringerCancer Immunology, Immunotherapy1432-08512025-08-0174911610.1007/s00262-025-04102-3A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signaturesKyle J. Hitscherich0Darryl Nousome1Aaron J. Dinerman2Victoria Dulemba3Frank J. Lowery4Naris Nilubol5Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of HealthCCR Collaborative Bioinformatics Resource (CCBR), Center for Cancer Research, NCI, NIHSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of HealthSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of HealthSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of HealthEndocrine Surgery Section, Surgical Oncology Program, National Cancer Institute, NIHAbstract Efforts to understand the tumor microenvironment through basic science research and the cancer genome atlas (TCGA) data analysis have led to the creation of unique immune transcriptomic signatures from tumor-infiltrating lymphocytes (TIL). However, no pan-cancer analysis has been conducted to compare the prognostic performance of these signatures using overall survival (OS) or progression-free interval (PFI) as endpoints. We compiled a library of 146 TIL-immune signatures and evaluated gene signature score correlation with OS and PFI for 9,961 available TCGA samples across 33 tumor types. Zhang CD8 TCS demonstrated higher accuracy in prognosticating both OS and PFI across the pan-cancer landscape; however, variability was seen across cancer types and germ cell origin. Cluster analysis compiled a group of six signatures (Oh.Cd8.MAIT, Grog.8KLRB1, Oh.TIL_CD4.GZMK, Grog.CD4.TCF7, Oh.CD8.RPL, Grog.CD4.RPL32) whose association with OS and PFI could potentially be conserved across multiple neoplasms.https://doi.org/10.1007/s00262-025-04102-3CancerImmunotherapySingle cell sequencingTumor microenvironmentTumor-infiltrating lymphocytes
spellingShingle Kyle J. Hitscherich
Darryl Nousome
Aaron J. Dinerman
Victoria Dulemba
Frank J. Lowery
Naris Nilubol
A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures
Cancer Immunology, Immunotherapy
Cancer
Immunotherapy
Single cell sequencing
Tumor microenvironment
Tumor-infiltrating lymphocytes
title A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures
title_full A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures
title_fullStr A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures
title_full_unstemmed A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures
title_short A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures
title_sort pan cancer comparative analysis of the cancer genome atlas transcriptomic til immune signatures
topic Cancer
Immunotherapy
Single cell sequencing
Tumor microenvironment
Tumor-infiltrating lymphocytes
url https://doi.org/10.1007/s00262-025-04102-3
work_keys_str_mv AT kylejhitscherich apancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT darrylnousome apancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT aaronjdinerman apancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT victoriadulemba apancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT frankjlowery apancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT narisnilubol apancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT kylejhitscherich pancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT darrylnousome pancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT aaronjdinerman pancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT victoriadulemba pancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT frankjlowery pancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures
AT narisnilubol pancancercomparativeanalysisofthecancergenomeatlastranscriptomictilimmunesignatures